Tengonermin, also known as NGR-hTNF, is a vascular-targeting drug. It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide.... This drug works by modifying the tumor microenvironment and increasing intratumoral chemotherapy penetration and T-cell infiltration.
- Mechanism
- Curator reviewed · 4 references
Tengonermin has highly selective homing to tumor blood vessels due to the NGR peptide portion binding specifically to a CD13 isoform (expressed selectively by endothelial cells of human tumor vessels during neoangiogenesis) which allows it to spare tumor-unrelated human tissues. This drug also increases apoptosis of angiogenic endothelial cells in vivo. The aforementioned effects significantly contribute to controlling the growth of tumors. Once the drug targets the tumor vasculature, multiple downstream effects occur, mediated by the interaction of both components of the molecule.
- Also known as
- NGR-hTNF
Resolves to
What you can answer from here — as of July 08, 2026
Which drugs share a target with Tengonermin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account